Mark Alvino Sells 15,000 Shares of Abeona Therapeutics (NASDAQ:ABEO) Stock

Abeona Therapeutics Inc. (NASDAQ:ABEO) Director Mark Alvino sold 15,000 shares of the firm’s stock in a transaction dated Thursday, November 13th. The shares were sold at an average price of $4.74, for a total value of $71,100.00. Following the sale, the director directly owned 62,252 shares in the company, valued at approximately $295,074.48. The trade was a 19.42% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Abeona Therapeutics Stock Down 1.8%

Shares of NASDAQ:ABEO traded down $0.08 during trading on Friday, reaching $4.45. The stock had a trading volume of 2,636,102 shares, compared to its average volume of 1,155,498. The firm’s 50-day simple moving average is $5.39 and its 200 day simple moving average is $5.98. The company has a current ratio of 6.73, a quick ratio of 6.65 and a debt-to-equity ratio of 0.09. Abeona Therapeutics Inc. has a one year low of $3.93 and a one year high of $7.54. The company has a market capitalization of $228.19 million, a P/E ratio of 6.36 and a beta of 1.45.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings results on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.17. As a group, research analysts expect that Abeona Therapeutics Inc. will post -1.16 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ABEO has been the subject of several research analyst reports. Weiss Ratings cut Abeona Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, October 24th. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Abeona Therapeutics in a research report on Monday, October 13th. Finally, Oppenheimer lifted their price objective on shares of Abeona Therapeutics from $19.00 to $20.00 and gave the company an “outperform” rating in a research note on Friday, August 15th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

Institutional Investors Weigh In On Abeona Therapeutics

Several hedge funds have recently bought and sold shares of ABEO. Wellington Management Group LLP lifted its stake in shares of Abeona Therapeutics by 64.1% in the 1st quarter. Wellington Management Group LLP now owns 153,121 shares of the biopharmaceutical company’s stock valued at $729,000 after purchasing an additional 59,832 shares during the period. OMERS ADMINISTRATION Corp raised its position in shares of Abeona Therapeutics by 11.0% in the first quarter. OMERS ADMINISTRATION Corp now owns 72,200 shares of the biopharmaceutical company’s stock worth $344,000 after acquiring an additional 7,155 shares during the period. Trexquant Investment LP boosted its stake in shares of Abeona Therapeutics by 74.1% during the 1st quarter. Trexquant Investment LP now owns 119,274 shares of the biopharmaceutical company’s stock worth $568,000 after acquiring an additional 50,758 shares in the last quarter. Newtyn Management LLC grew its position in shares of Abeona Therapeutics by 26.3% during the 1st quarter. Newtyn Management LLC now owns 480,000 shares of the biopharmaceutical company’s stock valued at $2,285,000 after acquiring an additional 100,000 shares during the period. Finally, Goldman Sachs Group Inc. increased its stake in shares of Abeona Therapeutics by 49.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 200,450 shares of the biopharmaceutical company’s stock valued at $954,000 after purchasing an additional 66,422 shares in the last quarter. Hedge funds and other institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.